Business Context and Reporting Period
This Form 8-K reports on the Annual Meeting of Stockholders held by AlloVir, Inc. (not Kalaris Therapeutics, Inc.) on May 17, 2022. The filing details the results of shareholder votes on director elections and the ratification of the independent auditor. As of the record date (March 22, 2022), there were 65,361,887 shares of common stock outstanding.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a current report regarding corporate governance events and does not contain financial statements.
Material Changes
No material financial changes are reported in this filing. The primary events are the successful election of Class II directors and the ratification of the accounting firm.
Guidance, Outlook, and Voting Results
Management commentary and financial guidance are not included in this filing. The following voting outcomes were reported:
- Proposal 1 (Director Election): Stockholders approved the election of Vikas Sinha and Malcolm Brenner, M.D., Ph.D., as Class II directors.
- Proposal 2 (Auditor Ratification): Stockholders approved the selection of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2022.
| Proposal | For | Against/Withhold | Abstain/Non-Votes |
|---|---|---|---|
| Election of Vikas Sinha | 47,229,880 | 4,036,755 (Withhold) | 10,745,678 (Broker Non-Votes) |
| Election of Malcolm Brenner | 48,449,496 | 2,817,139 (Withhold) | 10,745,678 (Broker Non-Votes) |
| Ratification of Auditor | 61,754,011 | 250,317 | 7,985 |
Investor Verification Checklist
- Verify the company name is AlloVir, Inc. (Ticker: ALVR), as the request metadata incorrectly listed Kalaris Therapeutics, Inc.
- Confirm the tenure of the newly elected directors (Vikas Sinha and Malcolm Brenner) extends until the 2025 Annual Meeting.
- Review the Definitive Proxy Statement filed on April 6, 2022, for detailed biographies of the directors and further context on the auditor selection.
- Note that this filing contains no financial performance data; refer to the most recent 10-K or 10-Q for financial metrics.